Clinical Study
Perspectives of CB1 Antagonist in Treatment of Obesity: Experience of RIO-Asia
Table 1
Demographic characteristics and comorbidities.
| | Placebo () | Rimonabant 20 mg () | Overall () |
| | Age (years) | | | | | Overall, mean (SD) | 35.3 (10.5) | 36.7 (10.8) | 36.0 (10.7) | | Age group, (%) | | | | | <18 | 0 | 1 (0.3%) | 1 (0.2%) | | 294 (90.7%) | 273 (85.8%) | 567 (88.3%) | | 27 (8.3%) | 41 (12.9%) | 68 (10.6%) | | ≥65 | 3 (0.9%) | 3 (0.9%) | 6 (0.9%) | | Gender, (%) | | | | | Male | 103 (31.8%) | 99 (31.1%) | 202 (31.5%) | | Female | 221 (68.2%) | 219 (68.9%) | 440 (68.5%) | | Country, (%) | | | | | China | 121 (37.3%) | 119 (37.4%) | 240 (37.4%) | | Republic of Korea | 101 (31.2%) | 99 (31.1%) | 200 (31.2%) | | Taiwan | 102 (31.5%) | 100 (31.4%) | 202 (31.5%) | | Comorbidities, (%) | | | | | Hypertension | 42 (13.0%) | 51 (16.0%) | 93 (14.5%) | | Dyslipidemia | 73 (22.5%) | 73 (23.0%) | 146 (22.7%) |
|
|
